We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other most ...

We recently published a list of 10 Value Stocks in Ken Fisher’s Portfolio. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other value stocks in ...

Yet JNJ ’s scale (it has a $369 billion market cap) and pipeline of 10 drugs targeting $5 billion in peak sales, mitigate them. In a tariff-rattled market, ...

Johnson & Johnson has seen its top line grow at an average rate of 4.1% over the last 3 years (vs. increase of 6.3% for S&P 500); Its revenues have grown 4.3% from $85 Bil to $89 Bil in the last ...

Johnson & Johnson Inc. (NYSE: JNJ) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan.

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

JNJ Quantitative Stock Analysis February 11, 2025 — 09:00 am EST Written by John Reese for Validea -> ...

Johnson & Johnson forms a Death Cross as JNJ stock drops below key moving averages, signaling bearish momentum. Strategic moves in dermatology, including a licensing deal for eczema drug KP-723 ...

Overall, the performance of these stocks with respect to the index has been quite volatile. Returns for BMY stock were 3% in 2021, 19% in 2022, and -26% in 2023, while that for JNJ were 11%, 6% ...